Metformin reduces RhoA activity and activates AMPK (20, 21), while Fasudil, a selective RhoA inhibitor used to treat diabetic nephropathy, improves insulin signaling and nephropathy by correcting glucose and lipid homeostasis in obese Zucker rats (22–24). This evidence concerns the gene PRKAA2 and Nephropathy.